绥美凯适应症是什么？

Suimeike (dolute abalamib tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Suimeikai (dolutegravir tablets) is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

At present, Suimeike (dolute abalamib tablets) has been approved in more than 100 countries, and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the lifespans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of Suimeike (dolute abalamib tablets) fills this gap and meets the urgent need for convenient medication use by doctors and patients."

It can be seen that Suimeikai (dolute abalamib tablets) is a new drug used to treat AIDS and brings new hope to AIDS patients. AIDS is an infectious disease that can be transmitted through sexual contact, blood, and mother-to-child transmission. Currently, there is still a lack of effective drugs to cure HIV infection worldwide. Suimeikai (Dolutea Paramid Tablets) can only reduce the viral load to the maximum and lasting extent and improve the patient's quality of life.